The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CSL’s Andembry (garadacimab) to prevent ...

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.

The swelling started with almost no warning, then seven-year-old Fiona Wardman’s hand ballooned like a rubber glove hooked to ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved garadacimab (brand name Andembry) for patients aged 12 years and older with hereditary angioedema (HAE) to ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...

JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...

Australia’s Therapeutic Goods Administration (TGA) has approved CSL Ltd.’s Andembry (garadacimab) for preventing recurrent hereditary angioedema attacks, marking the first global approval for the drug ...

JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...

Perspective from Douglas H. Jones, MD Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study published in The Journal of Allergy ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...